Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Silo Pharma ( (SILO) ) has shared an announcement.
On July 8, 2025, Silo Pharma, Inc. entered into an Agreement with the University of Maryland, Baltimore, terminating a previous Master License Agreement from February 12, 2021. This new Agreement grants Silo Pharma an exclusive evaluation license and an option to negotiate a commercial license for intellectual property related to central nervous system-homing peptides, aimed at treating neuroinflammatory diseases globally. The Agreement, effective until March 31, 2026, allows Silo Pharma to potentially secure a sublicensable, royalty-bearing license, enhancing its strategic positioning in the biotechnology sector.
More about Silo Pharma
Silo Pharma, Inc. operates in the biotechnology industry, focusing on developing innovative therapeutics for neuroinflammatory diseases. The company leverages intellectual property related to central nervous system-homing peptides to advance its research and development efforts.
Average Trading Volume: 1,012,291
Technical Sentiment Signal: Sell
Current Market Cap: $4.41M
Find detailed analytics on SILO stock on TipRanks’ Stock Analysis page.